X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA BIOCON LTD AJANTA PHARMA/
BIOCON LTD
 
P/E (TTM) x 28.7 84.4 34.0% View Chart
P/BV x 11.8 7.9 148.8% View Chart
Dividend Yield % 0.5 0.2 325.3%  

Financials

 AJANTA PHARMA   BIOCON LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
BIOCON LTD
Mar-17
AJANTA PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,7201,162 148.0%   
Low Rs1,103483 228.6%   
Sales per share (Unadj.) Rs194.6194.6 100.0%  
Earnings per share (Unadj.) Rs45.234.4 131.4%  
Cash flow per share (Unadj.) Rs50.348.3 104.2%  
Dividends per share (Unadj.) Rs8.001.00 800.0%  
Dividend yield (eoy) %0.60.1 466.0%  
Book value per share (Unadj.) Rs132.0241.9 54.6%  
Shares outstanding (eoy) m88.77200.00 44.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.34.2 171.6%   
Avg P/E ratio x31.223.9 130.6%  
P/CF ratio (eoy) x28.117.0 164.7%  
Price / Book Value ratio x10.73.4 314.5%  
Dividend payout %17.72.9 608.7%   
Avg Mkt Cap Rs m125,299164,440 76.2%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m2,5707,470 34.4%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m17,27538,911 44.4%  
Other income Rs m1661,571 10.6%   
Total revenues Rs m17,44240,482 43.1%   
Gross profit Rs m5,8079,795 59.3%  
Depreciation Rs m4512,772 16.3%   
Interest Rs m49260 18.8%   
Profit before tax Rs m5,4748,334 65.7%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,616 90.3%   
Profit after tax Rs m4,0146,881 58.3%  
Gross profit margin %33.625.2 133.5%  
Effective tax rate %26.719.4 137.5%   
Net profit margin %23.217.7 131.4%  
BALANCE SHEET DATA
Current assets Rs m7,63940,477 18.9%   
Current liabilities Rs m2,71516,783 16.2%   
Net working cap to sales %28.560.9 46.8%  
Current ratio x2.82.4 116.7%  
Inventory Days Days4360 72.5%  
Debtors Days Days7983 95.0%  
Net fixed assets Rs m6,91445,073 15.3%   
Share capital Rs m1771,000 17.7%   
"Free" reserves Rs m11,44247,377 24.2%   
Net worth Rs m11,72148,377 24.2%   
Long term debt Rs m14921,082 0.7%   
Total assets Rs m14,81493,942 15.8%  
Interest coverage x112.933.1 341.7%   
Debt to equity ratio x00.4 2.9%  
Sales to assets ratio x1.20.4 281.5%   
Return on assets %27.47.6 360.8%  
Return on equity %34.214.2 240.8%  
Return on capital %46.512.6 369.1%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42212,988 80.2%   
Fx outflow Rs m1,6787,899 21.2%   
Net fx Rs m8,7445,089 171.8%   
CASH FLOW
From Operations Rs m3,2646,400 51.0%  
From Investments Rs m-2,093-4,985 42.0%  
From Financial Activity Rs m-1,186-1,775 66.8%  
Net Cashflow Rs m-15-473 3.1%  

Share Holding

Indian Promoters % 73.8 40.4 182.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 1.6 8.4 18.5%  
FIIs % 7.6 10.7 71.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.9 85.4%  
Shareholders   20,968 109,995 19.1%  
Pledged promoter(s) holding % 4.4 0.0 10,975.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Airtel, Idea Down by 5%(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 24, 2018 01:49 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - STRIDES SHASUN LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS